Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.4K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.2K
3.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
4.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.9K
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance.

Pharmacological research·2026
Same author

Functional germline variants together with somatic mutations alter the integrity of cancer hallmark regulatory networks.

Genome medicine·2026
Same author

Overweight and obesity increase breast cancer risk in postmenopausal women: a meta-analysis of 38 observational studies.

GeroScience·2026
Same author

IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy.

NPJ precision oncology·2026
Same author

TNMplot: An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene expression analysis.

British journal of pharmacology·2026
Same author

HDAC7 is a key factor for the germinal center reaction and its underexpression is associated with DLBCL prognosis.

Journal of immunology (Baltimore, Md. : 1950)·2026

Related Experiment Video

Updated: Mar 15, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

17.1K

Cancer heterogeneity determined by functional proteomics.

A Marcell Szász1, Balázs Győrffy2, György Marko-Varga3

  • 1MTA-TTK Lendület Cancer Biomarker Research Group, Hungarian Academy of Sciences, 1117 Budapest, Hungary; Second Department of Pathology, Semmelweis University, 1091 Budapest, Hungary; Centre of Excellence in Biological and Medical Mass Spectrometry, Biomedical Centre D13, Lund University, 221 84 Lund, Sweden; Clinical Protein Science & Imaging, Biomedical Centre, Dept. of Biomedical Engineering, Lund University, BMC D13, 221 84 Lund, Sweden.

Seminars in Cell & Developmental Biology
|August 30, 2016
PubMed
Summary

This study reviews proteomics, protein expression, and imaging mass spectrometry in cancer research. Understanding these molecular details is key to advancing personalized medicine and developing effective cancer diagnostics and therapeutics.

Keywords:
BiomarkersCancer heterogeneityClinical studyGenomicsMultiple reaction monitoring (MRM)Parallel reaction monitoring (PRM)ProteomicsSingle reaction monitoring (SRM)

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

1.2K

Related Experiment Videos

Last Updated: Mar 15, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

17.1K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

1.2K

Area of Science:

  • Oncology
  • Proteomics
  • Molecular Biology

Background:

  • Cancer is a complex, multifactorial disease.
  • Tumor pathology and grading are crucial for diagnostics.
  • Proteomics aids in identifying therapeutic targets for drug development.

Purpose of the Study:

  • To provide a synopsis of tumor heterogeneity using proteomics, protein expression analysis, and imaging mass spectrometry.
  • To highlight the role of histopathological diagnostics and grading in cancer.
  • To discuss the importance of understanding protein-drug interactions for personalized medicine.

Main Methods:

  • Analysis of patient samples using proteomics.
  • Protein expression analysis.
  • Imaging mass spectrometry.

Main Results:

  • Proteomics studies are vital for pinpointing relevant targets in drug development.
  • Molecular profiling of protein-drug interactions is essential for efficacy and safety.
  • Personalized medicine relies on understanding basic mechanisms of drug action and binding.

Conclusions:

  • Proteomics plays a critical role in the fight against cancer.
  • Advancements in diagnostic, prognostic, and predictive tests are needed.
  • Addressing opportunities and challenges in proteomics will drive progress in cancer treatment.